Notice of Class Action Lawsuit Against Aquestive Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy AQST?
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that defendants made false and/or misleading statements and failed to disclose the true state of the New Drug Application (NDA) for Anaphylm, resulting in investor losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and achieved the largest securities class action settlement against a Chinese company in 2017, showcasing its strong capabilities in this field.
- Participation Instructions: Investors can visit Rosen Law Firm's website or call toll-free at 866-767-3653 for more information, ensuring they select qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AQST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AQST
Wall Street analysts forecast AQST stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.170
Low
6.00
Averages
9.00
High
12.00
Current: 4.170
Low
6.00
Averages
9.00
High
12.00
About AQST
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Notice of Class Action Lawsuit Against Aquestive Therapeutics
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that defendants made false and/or misleading statements and failed to disclose the true state of the New Drug Application (NDA) for Anaphylm, resulting in investor losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and achieved the largest securities class action settlement against a Chinese company in 2017, showcasing its strong capabilities in this field.
- Participation Instructions: Investors can visit Rosen Law Firm's website or call toll-free at 866-767-3653 for more information, ensuring they select qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
AQST Shareholder Alert: False Statements Impact Stock Price
- False Statements Allegation: The complaint alleges that AQST misled investors by providing positive statements while concealing significant adverse facts regarding its New Drug Application for Anaphylm, which has severely impacted shareholder confidence.
- FDA Deficiency Letter: On January 9, 2026, AQST disclosed that it received a letter from the FDA identifying deficiencies that hindered labeling discussions, indicating that the approval of Anaphylm would be delayed, thus affecting the company's future revenue expectations.
- Dramatic Stock Decline: Following the FDA announcement, AQST's stock plummeted from $6.21 per share on January 8, 2026, to $3.91 per share on January 9, representing a decline of over 37% in a single day, reflecting extreme market pessimism about the company's outlook.
- Shareholder Action Call: The Gross Law Firm urges shareholders who purchased AQST stock between June 16, 2025, and January 8, 2026, to register for participation in the class action lawsuit to protect their rights and seek recovery, with a deadline of May 4, 2026.
See More
Faruqi & Faruqi Encourages Investors to Contact Regarding Aquestive Losses
- Legal Action Reminder: Faruq & Faruqi LLP is investigating potential claims against Aquestive Therapeutics, Inc., particularly for investors who purchased or acquired securities between June 16, 2025, and January 8, 2026, indicating possible legal risks for the company.
- Investor Contact Information: The firm's Securities Litigation Partner, Josh Wilson, encourages affected investors to reach out directly, providing phone numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to discuss their legal rights and options.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action against the company is May 4, 2026, which may affect their rights to claim.
- Potential Market Impact: The initiation of legal investigations may negatively impact Aquestive's stock price, prompting investors to closely monitor developments to assess their investment risks.
See More
Class Action Lawsuit Filed Against Aquestive Therapeutics
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, seeking damages for investors who purchased securities between June 16, 2025, and January 8, 2026, indicating a significant loss of investor confidence in the company's future prospects.
- False Statement Allegations: The complaint alleges that the company made materially false and misleading statements during the relevant period, particularly regarding the optimistic timeline for the approval of its New Drug Application (NDA), which may have led investors to make uninformed investment decisions.
- Concealed Human Factor Risks: The lawsuit also highlights that Defendants concealed significant human factor risks associated with the use of Anaphylm sublingual film, which could materially impact the likelihood and timing of regulatory approval, exacerbating potential losses for investors.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by May 4, 2026, to share in any potential recovery from the lawsuit, underscoring the importance of legal action in protecting investor rights.
See More
Reminder of Class Action for Aquestive Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as attorney fees will be covered through a contingency fee arrangement, allowing them to pursue legal remedies without financial burden.
- Law Firm Background: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong capabilities and successful track record in this field.
- Case Details: The lawsuit alleges that Aquestive concealed the true state of its New Drug Application related to its sublingual film, particularly regarding human factors in usage and packaging, resulting in investor losses when the truth emerged, highlighting the importance of careful selection of legal counsel for investors.
See More
Class Action Lawsuit Filed Against Aquestive Therapeutics
- Class Action Initiation: Pomerantz LLP has announced a class action lawsuit against Aquestive Therapeutics, alleging securities fraud and other unlawful business practices, with investors required to apply as Lead Plaintiff by May 4, 2026.
- FDA Approval Delay: On January 9, 2026, Aquestive received a letter from the FDA identifying deficiencies in its New Drug Application for Anaphylm, preventing labeling discussions and leading to indefinite delays in approval, which could significantly impact future revenues.
- Stock Price Plunge: Following the FDA news, Aquestive's stock price fell by $2.30, or 37.04%, closing at $3.91 per share on January 9, 2026, indicating a pessimistic market outlook on the company's future prospects.
- Legal Firm Background: Pomerantz LLP is a prominent law firm specializing in class action litigation in securities and antitrust, with a long history of recovering multimillion-dollar damages for victims, underscoring its significant influence in the legal landscape.
See More
Notice of Class Action Lawsuit Against Aquestive Therapeutics
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that defendants made false and/or misleading statements and failed to disclose the true state of the New Drug Application (NDA) for Anaphylm, resulting in investor losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and achieved the largest securities class action settlement against a Chinese company in 2017, showcasing its strong capabilities in this field.
- Participation Instructions: Investors can visit Rosen Law Firm's website or call toll-free at 866-767-3653 for more information, ensuring they select qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
AQST Shareholder Alert: False Statements Impact Stock Price
- False Statements Allegation: The complaint alleges that AQST misled investors by providing positive statements while concealing significant adverse facts regarding its New Drug Application for Anaphylm, which has severely impacted shareholder confidence.
- FDA Deficiency Letter: On January 9, 2026, AQST disclosed that it received a letter from the FDA identifying deficiencies that hindered labeling discussions, indicating that the approval of Anaphylm would be delayed, thus affecting the company's future revenue expectations.
- Dramatic Stock Decline: Following the FDA announcement, AQST's stock plummeted from $6.21 per share on January 8, 2026, to $3.91 per share on January 9, representing a decline of over 37% in a single day, reflecting extreme market pessimism about the company's outlook.
- Shareholder Action Call: The Gross Law Firm urges shareholders who purchased AQST stock between June 16, 2025, and January 8, 2026, to register for participation in the class action lawsuit to protect their rights and seek recovery, with a deadline of May 4, 2026.
See More
Faruqi & Faruqi Encourages Investors to Contact Regarding Aquestive Losses
- Legal Action Reminder: Faruq & Faruqi LLP is investigating potential claims against Aquestive Therapeutics, Inc., particularly for investors who purchased or acquired securities between June 16, 2025, and January 8, 2026, indicating possible legal risks for the company.
- Investor Contact Information: The firm's Securities Litigation Partner, Josh Wilson, encourages affected investors to reach out directly, providing phone numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to discuss their legal rights and options.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action against the company is May 4, 2026, which may affect their rights to claim.
- Potential Market Impact: The initiation of legal investigations may negatively impact Aquestive's stock price, prompting investors to closely monitor developments to assess their investment risks.
See More
Class Action Lawsuit Filed Against Aquestive Therapeutics
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, seeking damages for investors who purchased securities between June 16, 2025, and January 8, 2026, indicating a significant loss of investor confidence in the company's future prospects.
- False Statement Allegations: The complaint alleges that the company made materially false and misleading statements during the relevant period, particularly regarding the optimistic timeline for the approval of its New Drug Application (NDA), which may have led investors to make uninformed investment decisions.
- Concealed Human Factor Risks: The lawsuit also highlights that Defendants concealed significant human factor risks associated with the use of Anaphylm sublingual film, which could materially impact the likelihood and timing of regulatory approval, exacerbating potential losses for investors.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by May 4, 2026, to share in any potential recovery from the lawsuit, underscoring the importance of legal action in protecting investor rights.
See More
Reminder of Class Action for Aquestive Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as attorney fees will be covered through a contingency fee arrangement, allowing them to pursue legal remedies without financial burden.
- Law Firm Background: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong capabilities and successful track record in this field.
- Case Details: The lawsuit alleges that Aquestive concealed the true state of its New Drug Application related to its sublingual film, particularly regarding human factors in usage and packaging, resulting in investor losses when the truth emerged, highlighting the importance of careful selection of legal counsel for investors.
See More
Class Action Lawsuit Filed Against Aquestive Therapeutics
- Class Action Initiation: Pomerantz LLP has announced a class action lawsuit against Aquestive Therapeutics, alleging securities fraud and other unlawful business practices, with investors required to apply as Lead Plaintiff by May 4, 2026.
- FDA Approval Delay: On January 9, 2026, Aquestive received a letter from the FDA identifying deficiencies in its New Drug Application for Anaphylm, preventing labeling discussions and leading to indefinite delays in approval, which could significantly impact future revenues.
- Stock Price Plunge: Following the FDA news, Aquestive's stock price fell by $2.30, or 37.04%, closing at $3.91 per share on January 9, 2026, indicating a pessimistic market outlook on the company's future prospects.
- Legal Firm Background: Pomerantz LLP is a prominent law firm specializing in class action litigation in securities and antitrust, with a long history of recovering multimillion-dollar damages for victims, underscoring its significant influence in the legal landscape.
See More
